Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
March 13, 2007

VentiRx’ Deal with Array Enhances its Postion in TLR-based Therapeutics

  • VentiRx Pharmaceuticals obtained exclusive, worldwide rights to Array BioPharma’s Toll-like receptor (TLR) program. The program contains a number of development candidates targeting TLRs to activate innate immunity. VentiRx expects to develop its first two candidates in oncology and allergy.

    "These novel small molecule compounds from Array represent a significant opportunity for VentiRx and are ideally suited for our core competencies," says Michael Kamdar, executive vp and CBO at VentiRx. "This licensing agreement, coupled with our $28.9 million financing, puts us in a strong position to develop novel TLR-based therapeutics."

    Array will receive an equity stake in VentiRx, an upfront payment, potential milestones, and royalties on product sales. Array also retains the option to acquire a 50% ownership position in all VentiRx clinical oncology products developed.

  • You’re all set! Thank you for subscribing to GEN Highlights.